Engineered inducible human CD40 receptor (CD40 (engineered inducible))

The engineered inducible human CD40 receptor is a modified version of the native CD40 receptor, a type I transmembrane protein and member of the tumor necrosis factor receptor superfamily, expressed primarily on B cells, dendritic cells, and other immune and non-immune cells[1]. In its native form, CD40 is essential for immune regulation, including B cell activation, antibody class switching, and dendritic cell function[1]. Engineering an "inducible" version typically refers to the insertion of regulatory elements allowing its expression or activation to be controlled experimentally, often in cell therapy or synthetic biology settings. Upon binding its ligand CD40L (CD154), CD40 activates downstream signaling pathways such as NF-κB, promoting immune cell activation and cytokine secretion[1][3]. Dysregulation of CD40 signaling is implicated in autoimmunity, inflammation, and various cancers[1]. Drugs targeting CD40 include monoclonal antibodies and CD40L fusion proteins, with both therapeutic (immune activation in cancer) and adverse (cytokine release, autoimmunity) effects[2][3]. The engineered inducible form is primarily used for research and therapeutic development to precisely modulate immune responses.

Other names

CD40 receptorTNFRSF5 (Tumor necrosis factor receptor superfamily member 5)Engineered CD40Inducible CD40 receptorHuman CD40 receptor

Agonist: CD40 activation leads to NF-κB pathway stimulation, cytokine secretion, and immune cell activation Antagonist/blocker: CD40 blockade can reduce inflammation/immune activation